Investor Centre

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) announced that the Food and Drug Administration (FDA) has completed a safety review of the company’s Investigational New Drug (IND) application for the pan-LOX inhibitor PXS-5505 and given Pharmaxis permission to proceed with a phase 1/2 clinical trial for the treatment of myelofibrosis in adults. 

Pharmaceutical research company Pharmaxis (ASX: PXS) today announced that its non-executive director Mr Edward Rayner has resigned from the Board effective 14 August 2020.

Mr Rayner joined the Pharmaxis Board in conjunction with a share placement to UK based Arix Bioscience plc in September 2018. At the time he was  the investment director leading the Arix investment. Mr Rayner has recently commenced a new executive position with a UK life science technology company, having left Arix earlier this year.

Pharmaxis Chairman Malcolm McComas said, “We will miss Ed’s contribution as an experienced global specialist biotech investor, but we understand his need to focus on his new position and wish him well.”

Pharmaceutical research company Pharmaxis Ltd (ASX: PXS) today announced an accelerated timeline on payment of the initial tranche of a US$10 million Bronchitol launch milestone following negotiation with its US licensee Chiesi Farmaceutici S.p.A. (Chiesi). US$7 million of the milestone will now be payable by Chiesi upon US approval of Bronchitol by the Food and Drug Administration (FDA) who have advised a Goal Action Date of 1 November 2020. Another US$3 million will remain payable on shipment by Pharmaxis of commercial launch stock in the first quarter of 2021.